articleThe LancetAug 1, 2005Closed access

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

Vienna General Hospital · Austrian Breast & Colorectal Cancer Study Group · +2 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

876
total citations
FWCI
69.11
Percentile
100%
References
38
Citations per year

Authors

13

Topics & keywords

Keywords
  • Anastrozole
  • Tamoxifen
  • Medicine
  • Breast cancer
  • Aromatase inhibitor
  • Oncology
  • Internal medicine
  • Hazard ratio
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding